Fiduciary Alliance LLC Boosts Stake in Hims & Hers Health, Inc. $HIMS

Fiduciary Alliance LLC grew its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 24.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 136,022 shares of the company’s stock after acquiring an additional 26,769 shares during the quarter. Fiduciary Alliance LLC’s holdings in Hims & Hers Health were worth $7,715,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of HIMS. Virtus Advisers LLC purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth about $26,000. Quaker Wealth Management LLC acquired a new position in Hims & Hers Health during the second quarter valued at approximately $29,000. Bessemer Group Inc. grew its stake in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after buying an additional 312 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the first quarter worth $30,000. Finally, Skandinaviska Enskilda Banken AB publ increased its position in shares of Hims & Hers Health by 408.2% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock worth $37,000 after acquiring an additional 600 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HIMS has been the topic of several recent research reports. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Barclays assumed coverage on Hims & Hers Health in a research note on Monday, December 8th. They set an “overweight” rating and a $48.00 price objective on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $68.00 target price on shares of Hims & Hers Health in a research report on Friday, September 12th. UBS Group set a $32.00 target price on Hims & Hers Health in a report on Tuesday, November 4th. Finally, BTIG Research restated a “buy” rating and issued a $85.00 price target on shares of Hims & Hers Health in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $45.50.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 23,187 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $36.81, for a total value of $853,513.47. Following the sale, the chief financial officer directly owned 70,232 shares of the company’s stock, valued at $2,585,239.92. This represents a 24.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 2,637 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $42.53, for a total transaction of $112,151.61. Following the transaction, the insider owned 155,856 shares in the company, valued at $6,628,555.68. This trade represents a 1.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 194,193 shares of company stock worth $10,329,018 in the last ninety days. 13.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Down 5.1%

Shares of NYSE HIMS opened at $34.98 on Thursday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. Hims & Hers Health, Inc. has a 1 year low of $23.97 and a 1 year high of $72.98. The stock’s 50-day simple moving average is $42.69 and its 200-day simple moving average is $48.78. The firm has a market cap of $7.96 billion, a price-to-earnings ratio of 64.77, a PEG ratio of 7.29 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same quarter last year, the business earned $0.32 EPS. Hims & Hers Health’s revenue for the quarter was up 49.2% compared to the same quarter last year. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its board has approved a share buyback program on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.